On Wednesday U.S. regulators granted approval to a new orally-administered treatment for multiple sclerosis.
Tecfidera, manufactured by Biogen Idec (NASDAQ:BIIB), received clearance from the Food and Drug Administration for oral treatments of adults with multiple sclerosis. Approval came after patients taking the drug in two trials experienced fewer symptom relapses, compared to those taking placebos, CBS News noted.
The drug is taken two times daily. It joins two other multiple sclerosis treatment from Biogen, which require injections. Pricing for Tecfidera will be announced next week.
Multiple sclerosis, which progressively impairs a person’s coordination, strength and vision, affects more than 400,000 people in the U.S.
Two other pill-based treatments for multiple sclerosis are currently on the market: Novartis‘ (NYSE:NVS) Gilenya and Sanofi’s (NYSE:SNY) Aubagio, which was approved last year.
Biogen Idec closed at $176.78 a share on Thursday.